| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 | Oct 14, 2025 | Zenas BioPharma, Inc. | 10% Owner | Buy | 92.5 | +126,315 | 2.57% | ✗ | $2.4M |
| Jul 16, 2025 | Jul 17, 2025 | CRISPR Therapeutics AG | Director | Buy | 100.0 | +989,812 | 94.36% | ✗ | $51.5M |
| Sep 16, 2024 | Sep 16, 2024 | Zenas BioPharma, Inc. | 10% Owner | Buy | 100.0 | +2,235,294 | 83.52% | ✗ | $38M |
| Mar 27, 2024 | Mar 28, 2024 | Nkarta, Inc. | Director | Buy | 100.0 | +2,000,000 | 150.00% | ✗ | $20M |
| May 11, 2023 | May 15, 2023 | Arcellx, Inc. | 10% Owner | Sell | 15.0 | -1,012,833 | -18.42% | ✗ | $45.6M |
| Dec 16, 2022 | Dec 20, 2022 | Design Therapeutics, Inc. | Director | Buy | 100.0 | +900,000 | 16.00% | ✗ | $7.6M |
| Apr 28, 2022 | Apr 29, 2022 | Nkarta, Inc. | Director | Buy | 100.0 | +1,333,333 | 100.00% | ✗ | $20M |
| Feb 8, 2022 | Feb 10, 2022 | Arcellx, Inc. | 10% Owner | Buy | 100.0 | +1,666,667 | 43.48% | ✗ | $25M |
| Mar 30, 2021 | Apr 1, 2021 | Design Therapeutics, Inc. | Director | Buy | 93.8 | +250,000 | 4.65% | ✗ | $5M |
| Oct 24, 2016 | Oct 26, 2016 | CRISPR Therapeutics AG | Director | Buy | 85.0 | +66,500 | 2.11% | ✗ | $931K |